ADMA BIOLOGICS, INC. (ADMA) - Dilution Analysis

10-Q filing | 237.8M shares outstanding

10-K filing | 233.1M shares outstanding

10-Q filing | 234.6M shares outstanding

10-Q filing | 232.4M shares outstanding

10-Q filing | 228.9M shares outstanding

10-K filing | 224.0M shares outstanding

10-Q filing | 225.3M shares outstanding

10-Q filing | 222.7M shares outstanding

10-Q filing | 221.9M shares outstanding

8-K filing: ADMA Biologics issued warrants to purchase 2,391,244 shares of common stock to entities affiliated with Hayfin as consideration for Amendment No. 2 to the Credit Agreement.

10-K filing | 222.2M shares outstanding

8-K filing: ADMA Biologics, Inc. completed the sale of 24,125,873 shares of common stock, including the full exercise of the Underwriters' option to purchase additional shares, for gross proceeds of approximately $69 million. ($69.0M proceeds)

8-K filing: ADMA Biologics, Inc. priced its underwritten public offering of 20,979,020 shares of common stock at a price of $2.86 per share, for gross proceeds of approximately $60 million. ($60.0M proceeds)

10-Q filing | 196.4M shares outstanding

10-Q filing | 196.4M shares outstanding

10-Q filing | 195.9M shares outstanding

10-K filing | 195.9M shares outstanding

10-Q filing | 195.8M shares outstanding

8-K filing: ADMA Biologics, Inc. completed the sale of 57.5 million shares of common stock at a gross proceeds of $57.5 million before deducting the underwriting discounts and commissions and fees and expenses. ($57.5M proceeds)

8-K filing: ADMA Biologics, Inc. priced an underwritten public offering of 50 million shares of common stock at $1.00 per share, with an option for underwriters to purchase up to an additional 7.5 million shares. ($50.0M proceeds)

10-Q filing | 127.4M shares outstanding

S-3/A filing: This is an S-3/A filing for ADMA Biologics, Inc. registering common stock, preferred stock, debt securities, warrants and units for a total aggregate offering price of $250,000,000.

S-3 filing: The filing is an S-3 registration statement for an at-the-market offering of common stock with an aggregate offering price of up to $50,000,000 through Jefferies LLC, acting as agent.

10-Q filing | 123.0M shares outstanding

10-K filing | 121.3M shares outstanding

8-K filing: ADMA Biologics, Inc. entered into Amendment No. 2 to its Credit Agreement, providing for an additional $15.0 million senior secured term loan and issuing a warrant to Perceptive Credit Holdings II, LP to purchase 2,390,000 shares of Common Stock.

10-Q filing | 89.6M shares outstanding

10-Q filing | 86.3M shares outstanding

10-Q filing | 59.3M shares outstanding

10-K filing | 46.4M shares outstanding

8-K filing: ADMA Biologics, Inc. completed the sale of 3,525,000 shares of common stock pursuant to the exercise of the Underwriters' option, receiving gross proceeds of approximately $12.3 million. ($12.3M proceeds)

8-K filing: ADMA Biologics, Inc. completed the sale of 23,500,000 shares of common stock for gross proceeds of $82,250,000. ($82.25M proceeds)

8-K filing: ADMA Biologics, Inc. priced its public offering of 23,500,000 shares of common stock at a price of $3.50 per share, for gross proceeds of approximately $82,250,000, with an option for underwriters to purchase an additional 3,525,000 shares. ($82.25M proceeds)